Literature DB >> 8381190

Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation.

J P Donohue1, J A Thornhill, R S Foster, R G Rowland, R Bihrle.   

Abstract

Results with primary retroperitoneal lymphadenectomy in 464 patients with clinical stage A nonseminomatous germ cell testis cancer (1965 to 1989) were reviewed. The false-negative staging error by clinical methods remains at 30%. The relapse rate in pathological stage A cancer patients was 11% (37 of 323), with 2 deaths. For pathological stage B disease 64% of the patients were cured by retroperitoneal lymphadenectomy alone. With modern adjuvant chemotherapy no stage B tumor relapsed since 1979 and the survival rate was 100%. For all 25 years (464 patients) the relapse rate was 14% and the survival rate was 98.9% (3 cancer and 2 noncancer deaths). Because these results are based on preoperative clinical staging, they are directly comparable with series using radiotherapy or surveillance.

Entities:  

Mesh:

Year:  1993        PMID: 8381190     DOI: 10.1016/s0022-5347(17)36046-9

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  35 in total

Review 1.  Secondary surgery in germ cell tumors--when and how extensively should it be performed?

Authors:  Richard S Foster; Stephen Beck; Richard Bihrle
Journal:  World J Urol       Date:  2004-03-30       Impact factor: 4.226

2.  Canadian consensus guidelines for the management of testicular germ cell cancer.

Authors:  Lori Wood; Christian Kollmannsberger; Michael Jewett; Peter Chung; Sebastian Hotte; Martin O'Malley; Joan Sweet; Lynn Anson-Cartwright; Eric Winquist; Scott North; Scott Tyldesley; Jeremy Sturgeon; Mary Gospodarowicz; Roanne Segal; Tina Cheng; Peter Venner; Malcolm Moore; Peter Albers; Robert Huddart; Craig Nichols; Padraig Warde
Journal:  Can Urol Assoc J       Date:  2010-04       Impact factor: 1.862

3.  Three cycles of etoposide and cisplatin chemotherapy in clinical stage IS nonseminomatous testicular cancer.

Authors:  Zaza Mezvrishvili; Laurent Managadze
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

4.  High-risk clinical stage I NSGCT: the case for RPLND.

Authors:  Christopher Morash; Ilias Cagiannos
Journal:  World J Urol       Date:  2009-06-02       Impact factor: 4.226

Review 5.  Reducing morbidity of pelvic and retroperitoneal lymphadenectomy.

Authors:  Mark W Ball; Michael A Gorin; Mohamad E Allaf
Journal:  Curr Urol Rep       Date:  2013-10       Impact factor: 3.092

Review 6.  Critical evaluation of modified templates and current trends in retroperitoneal lymph node dissection.

Authors:  Shane Pearce; Zoe Steinberg; Scott Eggener
Journal:  Curr Urol Rep       Date:  2013-10       Impact factor: 3.092

7.  Evolution and controversies in the management of low-stage nonseminomatous germ-cell tumors of the testis.

Authors:  G Pizzocaro; N Nicolai; R Salvioni
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

8.  [Management of complications after residual tumor resection for metastatic testicular cancer].

Authors:  A Lusch; M Zaum; C Winter; P Albers
Journal:  Urologe A       Date:  2014-07       Impact factor: 0.639

Review 9.  Management of patients with low-stage nonseminomatous germ cell testicular cancer.

Authors:  Andrew J Stephenson; Joel Sheinfeld
Journal:  Curr Treat Options Oncol       Date:  2005-09

10.  Risk-adapted management for patients with clinical stage I non-seminomatous germ cell tumour of the testis.

Authors:  Soner Guney; Nese Guney; Nurettin Cem Sonmez; Erbil Ergenekon
Journal:  Med Oncol       Date:  2008-09-26       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.